Scribe Therapeutics Inc. (SCTX) Stock Ticker
SCTX right now
Market factors today
Unlock the full SCTX picture
About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
SCTX stock facts
| Ticker symbol | SCTX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $344.4M |
| CEO | Benjamin L. Oakes |
| Employees | 89 |
| Headquarters | Alameda, CA, US |
| IPO date | 2026-07-24 |
| Website | www.scribetx.com |
What you can see for SCTX on Tickr
Live SCTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SCTX report.
Rankings
FAQ
What is the ticker symbol for Scribe Therapeutics Inc.?
The ticker symbol for Scribe Therapeutics Inc. is SCTX, listed on the NASDAQ.
What is SCTX?
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.